Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C19-IG 20% in Asymptomatic COVID-19 Outpatients
NCT04847141Phase 3Terminated
- Sponsor
- Grifols
- Start
- Apr 2021
- Primary completion
- Nov 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of Anti-COVID-19 Immune Globulin (Human) in coronavirus disease 2019 (COVID-19), sponsored by Grifols. Started Apr 2021; status: terminated.
02
Drugs
Anti-COVID-19 Immune Globulin (Human)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04847141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04847141.